BGB601 (ADCT-601) is an antibody drug conjugate (ADC) composed of a humanised IgG1 antibody against human AXL that is linked to a cytotoxin. In pre-clinical experiments, BGB601 demonstrated potent and specific in vitro and in vivo anti-tumour activity in various cancer-derived models with different levels of membranous AXL. BGB601 is currently undergoing Phase I trial and out-licensed to ADC Therapeutics S.a.r.l.
Selective AXL inhibitors
Footer
